25 December 2019
DBL Pharma has signed an agreement with GlaxoSmithKline (GSK) Bangladesh Ltd. to acquire some dermatological product manufacturing and quality control equipments used in GSK’s Chittagong factory. Before closing their business in Bangladesh in 2018 GSK used to manufacture popular brands like Betnovate, Dermovate & Neobacrin using this facility. The regulatory authority for Drugs has been formally notified of this deal between GSK and DBL on 22 December 2019. To re-introduce alternatives of discontinued GSK dermatological products using the same technology for the patients of Bangladesh, DBL has entered into this agreement with GSK.
DBL Group, one of the leading Bangladeshi conglomerate, in line with their astounding success in export-oriented garments and ceramics business, is investing in Pharmaceuticals. With an investment of around BDT 700 Crore, a US FDA standard pharmaceutical DBL Pharma manufacturing plant is underway development at Kashimpur (Gazipur), which is expected to be fully operational by late 2021 by following standard & the guideline of US FDA. The factory is developed on around 10 acre land and will produce almost all dosage forms including tablets, capsules, syrups, injections and inhalers using high spec machineries sourced from Europe.